For Immediate Release: 10 May 2018
513-579-9911 x 12627
Medpace’s Flagship Site Programme for High-Achieving Sites
Exemplifies Commitment to Accelerating Clinical Research
CRN GM Receives Flagship Site Status
London, 10 May 2018 – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that CRN GM (Clinical Research Network, Greater Manchester) has achieved the status of a Flagship Site Network —the highest level of site certification in Medpace’s Flagship Site Programme. Medpace and CRN GM have aligned services over the past two years and collectively delivered outstanding success in respect to study recruitment, data quality and meeting timelines.
The Flagship Site Programme was created to build and strengthen industry and public health sector/site ties, to accelerate clinical development, and to strengthen project deliverables. Only the highest- achieving sites who consistently demonstrate excellence in feasibility, contracts, recruitment, retention, and quality are certified.
Since 2016, Medpace and CRN GM have worked collaboratively to pilot the integration of services offered by both organisations. The resulting success has provided excellence in feasibility and quality data, and acceleration in study start-up and patient recruitment, whilst also providing valuable public health sector insight and intelligence for Medpace.
The CRN GM support the delivery of health research across Greater Manchester, East Cheshire and East Lancashire. With the support of 14 NHS Trusts, 11 Clinical Commissioning Groups; and more than 500 GP practices, this partnership has effectively accelerated the clinical development process.
Together, Medpace and CRN GM have accomplished:
- Increasing patient accessibility to life changing therapeutics across North East England
- Delivered innovative treatments, diagnostics and strategies to improve patient quality of life and outcome
- Provided guidance to investigators along all parts of the clinical research pathway, from concept to closure
- Increased the speed and delivery of research whilst maintaining quality and most integral, patient centricity
“Medpace is delighted to announce the formalisation of CRN GM’s status as a Flagship Site Network in recognition of its contribution and acceleration of clinical research,” commented Andrew Masih, Medpace Executive Director. “CRN GM is an excellent example of a research network whose personnel, processes, and overriding commitment to patient care exemplify the characteristics of an elite Flagship Site. We look forward to continuing to build and enhance our relationship and most importantly, work towards our shared goal of transforming the clinical development process for the benefits of patients.”
The Medpace/CRN GM relationship will strengthen crucial industry and healthcare relationships with key sites including CRN GM’s host trust, The Christie, a leading expert in cancer care, research and education. Medpace and The Christie will collaborate to offer patients’ access to specific cancer studies and clinical trials, further bridging the gap between industry and public health services to directly benefit those most in need.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,600 people across 35 countries.
About CRN GM
NIHR Clinical Research Greater Manchester (CRN GM) supports the delivery of health research across Greater Manchester, East Cheshire and East Lancashire. We are committed to delivering research which improves our patients’ health and NHS services. Covering a geographical footprint containing around three million people, we work closely with 14 NHS Trusts; 11 Clinical Commissioning Groups, and more than 500 GP practices. CRN GM continues to surpass its targets set by the NIHR; in 2017/18 we recruited more than 43,700 patients across 1,022 studies, comfortably meeting the target of 39,626.